cDC1 and/or cDC2 activation, which has not been previously reported or characterized in response to BH, is an essential step in the cancer immunity cycle as it is required for effective T cell priming and activation to elicit anti-tumor immunity. The gene discussed is MPPE1; the disease is cancer.